ATE257152T1 - N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia - Google Patents
N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasiaInfo
- Publication number
- ATE257152T1 ATE257152T1 AT98959050T AT98959050T ATE257152T1 AT E257152 T1 ATE257152 T1 AT E257152T1 AT 98959050 T AT98959050 T AT 98959050T AT 98959050 T AT98959050 T AT 98959050T AT E257152 T1 ATE257152 T1 AT E257152T1
- Authority
- AT
- Austria
- Prior art keywords
- benzyl
- treatment
- indenylaceamide
- neoplasia
- derivative
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/56—Amides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D215/14—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
- C07D237/02—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings
- C07D237/06—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D237/08—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
- C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Quinoline Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyridine Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US08/989,353 US5948779A (en) | 1997-12-12 | 1997-12-12 | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| US09/206,245 US6066634A (en) | 1997-12-12 | 1998-12-07 | Substituted condensation products of N-benzyl-3-indenylacetamides heterocyclic aldehydes for neoplasia |
| PCT/GB1998/003712 WO1999031065A1 (en) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylacetamides derivatives for treating neoplasia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE257152T1 true ATE257152T1 (de) | 2004-01-15 |
Family
ID=26901185
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT98959050T ATE257152T1 (de) | 1997-12-12 | 1998-12-11 | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US6166053A (de) |
| EP (1) | EP1044187B1 (de) |
| JP (1) | JP4307719B2 (de) |
| CN (1) | CN100436418C (de) |
| AT (1) | ATE257152T1 (de) |
| AU (1) | AU752072B2 (de) |
| BR (1) | BR9813540A (de) |
| CA (1) | CA2314339C (de) |
| CZ (1) | CZ298826B6 (de) |
| DE (1) | DE69820908T2 (de) |
| ES (1) | ES2212383T3 (de) |
| HU (1) | HU227153B1 (de) |
| IL (1) | IL136603A0 (de) |
| NO (1) | NO317097B1 (de) |
| NZ (1) | NZ504958A (de) |
| PL (1) | PL196936B1 (de) |
| TR (1) | TR200001687T2 (de) |
| WO (1) | WO1999031065A1 (de) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4307719B2 (ja) * | 1997-12-12 | 2009-08-05 | セル パスウェイズ インコーポレイテッド | 新形成治療用のｎ−ベンジル−３−インデニルアセトアミド誘導体 |
| IL132366A0 (en) * | 1998-10-15 | 2001-03-19 | Cell Pathways Inc | Methods for identifying compounds for inhibition of neoplastic lesions and pharmaceutical compositions containing such compounds |
| US20020006926A1 (en) * | 2000-04-19 | 2002-01-17 | Roylance H. H. | Use of cyclic GMP-specific phosphodiesterase inhibitors for treatment of parkinson's disease |
| DE10058663A1 (de) * | 2000-11-25 | 2002-05-29 | Merck Patent Gmbh | Verwendung von Thienopyrimidinen |
| WO2002067936A1 (en) * | 2001-02-21 | 2002-09-06 | Cell Pathways, Inc. | Methods for treatment of inflammatory bowel disease |
| DE10135815A1 (de) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Verwendung von 2-Alkoxyphenyl-substituierten Imidazotriazinonen |
| US6479493B1 (en) * | 2001-08-23 | 2002-11-12 | Cell Pathways, Inc. | Methods for treatment of type I diabetes |
| US20030073711A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of scleroderma |
| US20030073740A1 (en) * | 2001-08-23 | 2003-04-17 | Whitehead Clark M. | Methods for treatment of lupus erythematosus |
| CN100398522C (zh) * | 2003-08-20 | 2008-07-02 | Irm责任有限公司 | 组织蛋白酶s的抑制剂 |
| US6995622B2 (en) * | 2004-01-09 | 2006-02-07 | Robert Bosh Gmbh | Frequency and/or phase compensated microelectromechanical oscillator |
| WO2005120279A2 (en) | 2004-06-02 | 2005-12-22 | Merit Diamond Corporation | Comfort interior for jewelry and jewelry including that interior |
| CN1332930C (zh) * | 2005-08-05 | 2007-08-22 | 中国科学院上海有机化学研究所 | 制备乙氰菊酯前体的方法 |
| AU2007205208B2 (en) * | 2006-01-04 | 2012-11-01 | Southern Research Institute | Derivatives of sulindac, use thereof and preparation thereof |
| WO2009022756A1 (ja) * | 2007-08-13 | 2009-02-19 | Katayama Chemical Industries Co., Ltd. | 虚血性疾患の診断及び治療 |
| EP2365746B1 (de) * | 2008-11-04 | 2014-07-16 | Wellstat Therapeutics Corporation | Synthese von (phenylalkyloxy)phenyloxobutansäuren |
| US10566838B2 (en) | 2009-08-07 | 2020-02-18 | Auckland Uniservices Limited | Inductive power transfer system |
| US9862698B2 (en) * | 2014-12-16 | 2018-01-09 | Adt Pharmaceuticals, Inc. | Indenyl compounds, pharmaceutical compositions, and medical uses thereof |
| US20160168108A1 (en) | 2014-12-16 | 2016-06-16 | Adt Pharmaceuticals, Inc. | Method of treating or preventing ras-mediated diseases |
| WO2019210223A1 (en) | 2018-04-26 | 2019-10-31 | Adt Pharmaceuticals, Llc | Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0508586B1 (de) * | 1991-03-08 | 1995-05-31 | Fgn, Inc. | Substituierte Indenylverbindungen |
| US6063818A (en) * | 1996-06-13 | 2000-05-16 | Cell Pathways Inc. | Substituted benzylidene indenyl formamides, acetamides and propionamides |
| US5948779A (en) * | 1997-12-12 | 1999-09-07 | Cell Pathways, Inc. | Substituted condensation products of n-benzyl-3-indenyl acetamides with heterocyclic aldehydes |
| JP4307719B2 (ja) * | 1997-12-12 | 2009-08-05 | セル パスウェイズ インコーポレイテッド | 新形成治療用のｎ−ベンジル−３−インデニルアセトアミド誘導体 |
-
1998
- 1998-12-11 JP JP2000538992A patent/JP4307719B2/ja not_active Expired - Fee Related
- 1998-12-11 BR BR9813540-6A patent/BR9813540A/pt not_active Application Discontinuation
- 1998-12-11 ES ES98959050T patent/ES2212383T3/es not_active Expired - Lifetime
- 1998-12-11 PL PL341151A patent/PL196936B1/pl not_active IP Right Cessation
- 1998-12-11 EP EP98959050A patent/EP1044187B1/de not_active Expired - Lifetime
- 1998-12-11 AU AU14981/99A patent/AU752072B2/en not_active Ceased
- 1998-12-11 HU HU0100170A patent/HU227153B1/hu not_active IP Right Cessation
- 1998-12-11 AT AT98959050T patent/ATE257152T1/de not_active IP Right Cessation
- 1998-12-11 IL IL13660398A patent/IL136603A0/xx active IP Right Grant
- 1998-12-11 CN CNB988118955A patent/CN100436418C/zh not_active Expired - Fee Related
- 1998-12-11 TR TR2000/01687T patent/TR200001687T2/xx unknown
- 1998-12-11 NZ NZ504958A patent/NZ504958A/xx unknown
- 1998-12-11 WO PCT/GB1998/003712 patent/WO1999031065A1/en active IP Right Grant
- 1998-12-11 DE DE69820908T patent/DE69820908T2/de not_active Expired - Lifetime
- 1998-12-11 CA CA002314339A patent/CA2314339C/en not_active Expired - Fee Related
- 1998-12-11 CZ CZ20002157A patent/CZ298826B6/cs not_active IP Right Cessation
-
2000
- 2000-01-24 US US09/490,269 patent/US6166053A/en not_active Expired - Lifetime
- 2000-06-09 NO NO20002972A patent/NO317097B1/no not_active IP Right Cessation
- 2000-12-20 US US09/741,970 patent/US6426349B1/en not_active Expired - Fee Related
-
2002
- 2002-07-26 US US10/206,687 patent/US6610854B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US6610854B2 (en) | 2003-08-26 |
| PL341151A1 (en) | 2001-03-26 |
| JP4307719B2 (ja) | 2009-08-05 |
| AU752072B2 (en) | 2002-09-05 |
| TR200001687T2 (tr) | 2000-10-23 |
| CN100436418C (zh) | 2008-11-26 |
| US20030009033A1 (en) | 2003-01-09 |
| HU227153B1 (en) | 2010-08-30 |
| DE69820908T2 (de) | 2004-12-23 |
| EP1044187A1 (de) | 2000-10-18 |
| CA2314339C (en) | 2009-09-08 |
| ES2212383T3 (es) | 2004-07-16 |
| US6166053A (en) | 2000-12-26 |
| NO20002972D0 (no) | 2000-06-09 |
| CZ20002157A3 (cs) | 2000-10-11 |
| DE69820908D1 (de) | 2004-02-05 |
| CZ298826B6 (cs) | 2008-02-20 |
| NZ504958A (en) | 2003-03-28 |
| NO317097B1 (no) | 2004-08-09 |
| EP1044187B1 (de) | 2004-01-02 |
| IL136603A0 (en) | 2001-06-14 |
| WO1999031065A1 (en) | 1999-06-24 |
| CN1281436A (zh) | 2001-01-24 |
| AU1498199A (en) | 1999-07-05 |
| US6426349B1 (en) | 2002-07-30 |
| PL196936B1 (pl) | 2008-02-29 |
| CA2314339A1 (en) | 1999-06-24 |
| BR9813540A (pt) | 2000-10-10 |
| JP2002508358A (ja) | 2002-03-19 |
| NO20002972L (no) | 2000-08-09 |
| HUP0100170A1 (hu) | 2001-07-30 |
| HUP0100170A3 (en) | 2001-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69820908D1 (de) | N-benzyl-3-indenylaceamidderivative zur behandlung von neoplasia | |
| ATE350030T1 (de) | Nordihydroguaiaretinsäurederivate zur behandlung von tumoren | |
| ES2074867T3 (es) | Derivados de quinazolina para potenciar la actividad antitumoral. | |
| ATE222769T1 (de) | Verabreichung von gm-csf zur behandlung der gehirntumoren und verhütung deren wiederauftretens | |
| BR9912327A (pt) | Inibidores da uroquinase | |
| ATE239509T1 (de) | Konjugate zur behandlung von prostatakrebs | |
| TR199901949T2 (xx) | Lemfositik t�m�rler i�in �areler. | |
| DE69921981D1 (de) | ZUSAMMENSETZUNG AUS MUTIERTERN PEPTIDEN, DERIVATE DES hsp70 UND IHRE VERWENDUNG IN DER IMMUNTHERAPIE VON KREBS | |
| DE60036826D1 (de) | Verwendung von et743 in kombinationstherapie mit dexamethason zur behandlung von krebs | |
| AR016981A2 (es) | Polipeptidos sinteticos | |
| DE69940980D1 (de) | Rana pipiens proteine und deren verwendung in der behandlung von tumoren | |
| ATE383877T1 (de) | Identifikation von stoffen, die transkriptionelle antworten auf hypoxia modifizieren | |
| ATE233483T1 (de) | Wässrige lösung zum konservieren von gewebe und organen | |
| BR9907025B1 (pt) | Polissacarídeos sintéticos e uso dos mesmos | |
| ATE362765T1 (de) | Milchsäurebakterien mit anxiolytischer wirkung, und ihre verwendungen | |
| DE69732246D1 (de) | Gewebespezifische expression des retinoblastoma-proteins | |
| ATE353016T1 (de) | Chelatiertes 8-hydroxychinolin zur behandlung von epithelialen verletzungen | |
| ATE233093T1 (de) | Arzneimittel zur vermeidung und umkehrung der atherosklerose bei säugetieren | |
| ATE417926T1 (de) | Zusammensetzungen zur modulierung der länge von telomeren | |
| AU2821000A (en) | Matrix protein compositions for induction of apoptosis | |
| ATE383154T1 (de) | Kombinierte tumortherapie auf der basis von distamycin-acryloyl derivaten und radiotherapie | |
| DE60203726D1 (de) | Topische zusammensetzung enthaltend brucin und ihre verwendung zur behandlung von hautschäden | |
| FI964672A0 (fi) | Viljankäsittelymenetelmä, käsitelty vilja ja sen käyttö | |
| ATE336245T1 (de) | 3-heteroarylidenyl-2-indolinon derivate mit protein kinase modulierender activity und zur verwendung in der krebschemotherapie | |
| IT1296372B1 (it) | Procedimento ed impianto per il riciclaggio del sale utilizzato per la conservazione dei pellami grezzi. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |